Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse
Who is this study for? Patients with Multiple Myeloma
What treatments are being studied? [68Ga]Ga-PentixaFor
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXCR4 expression will also be assessed and \[68Ga\]Ga -PentixaFor/FDG discordances explored.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years
• Symptomatic MM patients according to IMWG criteria (12) requiring first-line treatment
• Written and signed informed consent (obtained on the screening day at the latest and before any investigation)
• ECOG (Eastern Cooperative Oncology Group) \< 2
• Patient affiliated to or beneficiary of the National Health Service
Locations
Other Locations
France
CHU Bordeaux
RECRUITING
Bordeaux
CHU Lille
NOT_YET_RECRUITING
Lille
HCL
NOT_YET_RECRUITING
Lyon
Nantes UH
RECRUITING
Nantes
APHP - Site Tenon
RECRUITING
Paris
Contact Information
Primary
Caroline Bodet Milin, MD, PhD
caroline.milin@chu-nantes.fr
0240084143
Time Frame
Start Date: 2021-09-21
Estimated Completion Date: 2030-05-21
Participants
Target number of participants: 45
Treatments
Experimental: [68Ga]Ga-PentixaFor
Related Therapeutic Areas
Sponsors
Leads: Nantes University Hospital